Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
We present a patient with a glioblastoma multiforme treated with bevacizumab who suffered a traumatic subarachnoid hemorrhage (SAH). Trascranial doppler revealed no evidence of vasoconstriction, which has been previously described in a bevacizumab-treated patient. Bevacizumab was resumed five weeks after the SAH without recurrence of bleeding or vasoconstriction. To our knowledge this is the first report of resumption of bevacizumab after SAH.
Department of Neurology, University of Chicago, Chicago, IL 60637, USA. rlukas@neurology.bsd.uchicago.edu
Rimas V
RV
Lukas
Fernando
F
Goldenberg
Martin K
MK
Nicholas
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005909:Glioblastoma / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020206:Subarachnoid Hemorrhage, Traumatic / Q000150:complications*; D000077204:Temozolomide; D014057:Tomography, X-Ray Computed; D017585:Ultrasonography, Doppler, Transcranial
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide